Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies.
about
Direct factor Xa inhibitors versus low molecular weight heparins or vitamin K antagonists for prevention of venous thromboembolism in elective primary hip or knee replacement or hip fracture repairNew anticoagulants for the prevention and treatment of venous thromboembolismVenous Thromboembolism in Cancer: An Update of Treatment and Prevention in the Era of Newer AnticoagulantsPostoperative management of hip fractures: interventions associated with improved outcomesPharmacological prevention of venous thromboembolism in orthopaedic surgeryTherapeutic approaches in arterial thrombosisThromboprophylaxis in patients undergoing total hip replacementReview of fondaparinux sodium injection for the prevention of venous thromboembolism in patients undergoing surgeryFondaparinux in the management of patients with ST-elevation acute myocardial infarctionManagement of acute coronary syndromes with fondaparinuxIncidence and cost burden of post-thrombotic syndromePharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacementIn vitro and in vivo characterization of a reversible synthetic heparin analog.Emerging options for thromboprophylaxis after orthopedic surgery: a review of clinical data.Clinical application of enoxaparin.Lepirudin: a bivalent direct thrombin inhibitor for anticoagulation therapy.Anti-platelet factor 4/heparin antibodies in orthopedic surgery patients receiving antithrombotic prophylaxis with fondaparinux or enoxaparinDabigatran etexilate: an oral direct thrombin inhibitor for prophylaxis and treatment of thromboembolic diseases.Clinical relevance of heparin-PF4 complex antibody in DVT after total joint replacementAnti-PF4/heparin antibody formation postorthopedic surgery thromboprophylaxis: the role of non-drug risk factors and evidence for a stoichiometry-based model of immunization.Fondaparinux sodium in the prophylaxis and treatment of deep vein thrombosis and pulmonary embolism.Fondaparinux: does it cause HIT? Can it treat HIT?Fondaparinux-associated heparin-induced thrombocytopeniaManagement of heparin-induced thrombocytopenia.Non-immune mediated thrombocytopenia caused by thromboprophylaxis for the perioperative care of urological surgery: A case report and review of the literatureCost effectiveness of venous thromboembolism pharmacological prophylaxis in total hip and knee replacement: a systematic review.The Perioperative Management of Antithrombotic Therapies Using Enoxaparin.Pharmacological and clinical differences between low-molecular-weight heparins: implications for prescribing practice and therapeutic interchange.Superior efficacy of new medicines?Diet as prophylaxis and treatment for venous thromboembolism?Emergency reversal of pentasaccharide anticoagulants: a systematic review of the literature.Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial.Venous thromboembolism after total joint arthroplasty: results from a Japanese multicenter cohort study.Novel factor Xa inhibitors for prevention and treatment of thromboembolic diseases.Italian intersociety consensus statement on antithrombotic prophylaxis in hip and knee replacement and in femoral neck fracture surgeryTendon tissue engineering and its role on healing of the experimentally induced large tendon defect model in rabbits: a comprehensive in vivo study.Selective factor Xa inhibition improves efficacy of venous thromboembolism prophylaxis in orthopedic surgery.Short- and long-acting synthetic pentasaccharides.Fondaparinux for prevention of venous thromboembolism in major orthopedic surgery.Thromboembolic disease after knee arthroplasty is rare in Southern Iran.
P2860
Q24187415-779BFDA3-9271-4B20-84B8-A225CE313AE3Q24681351-35AFEC37-2019-4C8B-88CF-E946DE9EB181Q26741697-2176AA80-3A46-497A-8244-384CB28F28A3Q26830646-A4C81B15-5094-45FF-9052-48B37EEE65ACQ28083067-F306B1EC-A9FC-4BA0-8A0E-42E4BC9D37B6Q28187576-1432C36D-D125-41F1-B767-0FBCA243E247Q28196381-1BB00E8B-54DA-49D8-81E4-CC0D4A6834D0Q28219412-C0B737CC-9B65-4364-93BA-E0D8AEC55D51Q28219415-1E54AB7C-FEED-4714-BF71-E96CD2395AC7Q28219642-1F17B61D-1A79-4107-9A4A-A94B46CBDF23Q28235459-EF72ABC2-5786-42DA-AF90-8FDB99BC3B33Q28245267-5882289F-A3D7-4444-BFBE-BA0AC4068132Q30710756-C336DA97-74A4-48AA-9377-46E532D24BD5Q30952695-10A7E6A9-75FE-4057-A2EC-1212571E0962Q33360866-106A173B-0501-4FB9-A023-D158F5A58D38Q33360869-492951C3-1755-41A9-BFE4-7B8319DDC280Q33367978-FCB58333-8A5C-419D-A725-6F171C6A04BEQ33381801-C3E445CF-B940-4461-8D2B-0C2E58656DD2Q33384243-BA1EAAAC-9C31-4064-B8ED-776294E8E5C1Q33387713-83F55E01-D226-4CDC-A44E-C55EE3585981Q33389966-1C020E2C-EA37-4255-AC5C-A66C4ED373FCQ33392864-F4B18C6D-04F6-44D1-A1AE-34149CDDDDEEQ33399335-E7DB3E83-DADC-4C7F-B845-7DC156D64E68Q33400573-6DC4BB6B-9E79-4502-A794-74FF60121943Q33434619-7ABD29F5-7241-4311-ADD1-088311CD27F9Q33605199-4F5B8E7B-DC68-4DE1-9925-7C7FBA0C84E6Q33661487-8A924DAD-AEAB-4E86-B712-0F9B6D8FB925Q33685447-7B6FCDD3-9482-4BDA-B830-49CF90449F90Q33785599-17FE17F2-C02F-404D-B7E8-440EF17864A2Q34078303-1BEAFDA3-5AC9-48AA-ADBC-D56FCA23E313Q34101751-44DB7F1D-7281-4791-AD5F-564E631E9A4EQ34343613-45B00BF2-3CD5-4C42-9D1D-766992894D21Q34468783-9AB39437-D105-4BC4-BF35-AF47D0B85A97Q34549913-781DE65F-7EA9-440B-B5B3-52F8533B06FAQ34641113-C6F45282-D962-4D78-9975-7974404B1B9BQ34988763-539AFB62-56F5-458B-A424-2EDF5A18031DQ35160253-0DCDFFEA-C55F-4D43-9AB6-36181682C674Q35219377-9548622D-227B-410C-85A8-DE975BCD93BFQ35562634-5CFDFDC5-DF05-4196-89DF-F24BB491F24AQ35573560-BA3580AB-59E4-4C07-BB06-A9E7513CDA9A
P2860
Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
Fondaparinux vs enoxaparin for ...... ndomized double-blind studies.
@en
Fondaparinux vs enoxaparin for ...... ndomized double-blind studies.
@nl
type
label
Fondaparinux vs enoxaparin for ...... ndomized double-blind studies.
@en
Fondaparinux vs enoxaparin for ...... ndomized double-blind studies.
@nl
prefLabel
Fondaparinux vs enoxaparin for ...... ndomized double-blind studies.
@en
Fondaparinux vs enoxaparin for ...... ndomized double-blind studies.
@nl
P2093
P1476
Fondaparinux vs enoxaparin for ...... andomized double-blind studies
@en
P2093
Alexander G G Turpie
Kenneth A Bauer
Michael R Lassen
P304
P356
10.1001/ARCHINTE.162.16.1833
P407
P577
2002-09-01T00:00:00Z